Biotech Values

[iwfal]

BMY’s new phase-3 Lambda trial in genotype-1b is unusual insofar as it has two variables: Lambda + Daclatasvir + ribavirin vs Pegasys + Incivek + ribavirin:

There are a variety of odd trials in HCV - e.g. the below "phase iii" trial by Abbot in G1 naives is lots of different variations of some Abbot orals without any component of SOC other than rib - i.e. no SOC treatment arm. Approvable? (Given the repeatability of HCV metrics, you'd think it would be approvable with good enough numbers - but who knows what the FDA will think)

http://www.clinicaltrials.gov/ct2/show/NCT01716585?term=hcv+-hiv&type=Intr&phase=2&rcv_s=01%2F01%2F2010&rcv_e=12%2F01%2F2012&rank=30